CTMX · NASDAQ
CytomX Therapeutics (CTMX) Stock Price & Fundamentals
CytomX Therapeutics (CTMX) closed at $798.85 on Oct 9, 2026, up 1.37% from the previous close of $788.06.
Share price, past year
1Y +56.39%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $798.85 |
| Sep 30, 2026 | $789.84 |
| Aug 31, 2026 | $746.44 |
| Jul 31, 2026 | $692.26 |
| Jun 30, 2026 | $698.88 |
| May 29, 2026 | $647.40 |
| Apr 30, 2026 | $618.48 |
| Mar 31, 2026 | $592.68 |
| Feb 27, 2026 | $613.37 |
| Jan 30, 2026 | $606.28 |
| Dec 31, 2025 | $590.57 |
| Nov 28, 2025 | $532.03 |
| Oct 31, 2025 | $512.13 |
Key statistics
- Market cap
- $135.95B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $18.30M
- Net income (TTM)
- −$79.65M
- Shares outstanding
- 170.2M
- Dividend yield
- —
- 52-week range
- $503.64 – $798.85
CytomX Therapeutics's market cap is $135.95B, based on a share price of $798.85 and 170.2M shares outstanding as of Dec 31, 2025.
Financials
CytomX Therapeutics reported revenue of $76.20M for fiscal 2025, down 44.82% from fiscal 2024.
CytomX Therapeutics reported a net loss of $17.37M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $76.20M | −44.8% | −$17.37M | −22.8% | — | −$75.81M |
| FY2024ended Dec 31, 2024 | $138.10M | +36.5% | $31.87M | 23.1% | — | −$86.54M |
| FY2023ended Dec 31, 2023 | $101.21M | +90.4% | −$569.00K | −0.6% | — | −$56.88M |
| FY2022ended Dec 31, 2022 | $53.16M | +42.5% | −$99.32M | −186.8% | — | −$112.53M |
| FY2021ended Dec 31, 2021 | $37.31M | −45.5% | −$115.87M | −310.5% | — | −$120.64M |
| FY2020ended Dec 31, 2020 | $68.43M | +154.4% | −$64.82M | −94.7% | — | $2.95M |
| FY2019ended Dec 31, 2019 | $26.90M | −54.8% | −$132.83M | −493.7% | — | −$143.98M |
| FY2018ended Dec 31, 2018 | $59.50M | −16.9% | −$84.60M | −142.2% | — | −$79.31M |
| FY2017ended Dec 31, 2017 | $71.62M | +376.1% | −$43.10M | −60.2% | −$1.16 | $168.81M |
| FY2016ended Dec 31, 2016 | $15.04M | — | −$58.90M | −391.5% | −$1.63 | −$4.21M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $1.42M | −$20.67M | — |
| Q1 FY2026ended Mar 31, 2026 | $10.26M | −$18.25M | — |
| Q4 FY2025ended Dec 31, 2025 | $663.00K | −$26.51M | — |
| Q3 FY2025ended Sep 30, 2025 | $5.96M | −$14.23M | — |
| Q2 FY2025ended Jun 30, 2025 | $18.66M | −$154.00K | — |
| Q1 FY2025ended Mar 31, 2025 | $50.92M | $23.53M | — |
| Q4 FY2024ended Dec 31, 2024 | $38.09M | $18.88M | — |
| Q3 FY2024ended Sep 30, 2024 | $33.43M | $5.74M | — |
Company profile
- Name
- CytomX Therapeutics, Inc.
- Ticker
- CTMX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 151 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001501989
Recent SEC filings
- Aug 6, 2026
- Aug 6, 2026
- Jul 27, 2026
- Jun 22, 2026
- Jun 3, 2026
- May 7, 2026
- May 7, 2026
- Mar 19, 2026
Frequently asked questions
What is CytomX Therapeutics's stock price?
CytomX Therapeutics (CTMX) closed at $798.85 on Oct 9, 2026, up 1.37% from the previous close of $788.06.
What is CytomX Therapeutics's market cap?
CytomX Therapeutics's market cap is $135.95B, based on a share price of $798.85 and 170.2M shares outstanding as of Dec 31, 2025.
How much revenue does CytomX Therapeutics make?
CytomX Therapeutics reported revenue of $76.20M for fiscal 2025, down 44.82% from fiscal 2024.
Does CytomX Therapeutics pay a dividend?
CytomX Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from CytomX Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures